CCNB1 and cancer: In conclusion, the results of this study convincingly demonstrate that diosgenin treatment results in a decreased level of cyclin B1 and increased phosphorylation of Cdc25CSer216 and Chk1Ser345, leading to cell cycle blockade at the G2/M phase, disruption of the ∆Ψm, and apoptotic cancer cell death.